Many bladder cancers that are resistant to chemotherapy and immunotherapy have mutations in the gene encoding a growth protein called fibroblast growth factor receptor (FGFR). Erdafitinib is a inhibitor of this FGFR growth protein and was studied in metastatic bladder cancer with FGFR mutations. In a trial of patients with these mutations, about 40% had… Read more »